Samotolisib is a novel dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR), and has undergone several phase-II clinical trials as a potential treatment for different cancers. The gene discussed is MTOR; the disease is cancer.